Abstract
In a prospective epidemiologic study, drug rashes were recorded more commonly in hospitalized medical patients in Israel than in North America. Detailed analysis of the Israeli data revealed that the risk of developing a rash is higher in dipyrone recipients than in non-recipients. The estimated risk of rahes attributable to the drug was 2.4 per cent, and about two-thirds of dipyrone rashes were mistakenly attributed to other drugs. Dipyrone, in the present series, was used only in Israel. When dipyrone recipients were excluded, the standardized rash rates in Israel and North America were similar.

This publication has 0 references indexed in Scilit: